Jacobs Levy Equity Management’s Tempest Therapeutics TPST Stock Holding History

Jacobs Levy Equity Management’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,033	Closed	-$355K	–	1108
2020 Q2	$355K	Buy	1,033 +925	+856%	+$369K	﹤0.01%	853
2020 Q1	$111K	Sell	108 -89	-45%	-$130K	﹤0.01%	955
2019 Q4	$259K	Sell	197 -2	-1%	-$2.82K	﹤0.01%	891
2019 Q3	$276K	Buy	+199	New	+$321K	﹤0.01%	794
2018 Q4	–	Sell	-66	Closed	-$140K	–	1067
2018 Q3	$140K	Hold	66	–	–	﹤0.01%	952
2018 Q2	$175K	Sell	66 -20	-23%	-$52.7K	﹤0.01%	964
2018 Q1	$204K	Buy	86 +38	+79%	+$114K	﹤0.01%	925
2017 Q4	$195K	Buy	+48	New	+$201K	﹤0.01%	910

Other funds holding TPST

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

Jacobs Levy Equity Management's TPST Position: Q3 2020 in Review

Jacobs Levy Equity Management sold out of Tempest Therapeutics (TPST) in Q3 2020, closing a stake of 1,033 shares — an estimated $355K sold.

Jacobs Levy Equity Management first reported a position in TPST in Q4 2017 and held it in 8 quarters. The position peaked at $355K in Q2 2020. 42 funds tracked by Wall St. Rank hold TPST as of Q3 2020.

Jacobs Levy Equity Management reported no remaining Tempest Therapeutics position as of Q3 2020 after selling out during the quarter.
Jacobs Levy Equity Management sold 1,033 Tempest Therapeutics shares in Q3 2020, an estimated $355K.
Jacobs Levy Equity Management first reported a position in Tempest Therapeutics in Q4 2017 and held it in 8 quarters.
Jacobs Levy Equity Management's Tempest Therapeutics position peaked at $355K in Q2 2020.
42 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2020, filed 16 Nov 2020.